Annals of Family Medicine
NOVEMBER 20, 2024
The first OA diagnosis in record must occur from 2009-2014 and index date is OA diagnosis date. OASI is the sum number of care elements offered (NSAID fills, opioid fills, intra-articular injection, knee x-ray, knee advanced imaging, and physical therapy). Final sample size was 435,731. Outcome Measures: Time to TKA.
Physician's Weekly
JUNE 26, 2025
For physicians, nurses, medical assistants, and support staff, workplace violence (WPV) is now a daily hazard, inflicting physical injury, emotional trauma, and eroding the quality of patient care. Violence in hospital emergency departments (EDs) has reached crisis levels. The severity of this problem has even made its way into pop culture.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Adventures of a Sick Doctor
JULY 4, 2024
I opened my diary (an actual physical book, not Outlook) and the silver ribbon is firmly stuck in the week of Wednesday 22nd May. Still though, he usually perks up when I come in, because he gets to show me my scans from November 2014 and compare them with now and we both applaud the wondrousness of the miracle that is my recovery.
FDA Law Blog
NOVEMBER 1, 2023
In fact, stakeholders have repeatedly challenged FDA’s assertions of authority in Citizen Petitions, public comments, and other forums. Premarket Approval or De Novo pathways).
BMJ
JULY 17, 2020
quarantine-breakers”) or video clips of people shouting at or even physically assaulting Wuhanese or people who visited Wuhan after the outbreak. 2014 (28 August). The content of many social media posts in China have stigmatized Wuhan or Wuhanese, for example posts engaging in name-calling (e.g., doi:10.3389/fcomm.2020.00039
FDA Law Blog
JANUARY 12, 2025
Since that time, it was formalized in FDA regulations (21 CFR 314 Subpart H) in 1992, codified in the Food, Drug, & Cosmetic Act by FDAMA (21 USC 356(c)) in 1997, revised by FDASIA in 2012, and described in guidance, most importantly, in the 2014 Expedited Programs for Serious Conditions Drugs and Biologics (2014 Guidance).
FDA Law Blog
FEBRUARY 29, 2024
A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. FDA-2022-E-3124 ).
Expert insights. Personalized for you.
130 
Let's personalize your content